Compare JAKK & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAKK | SRZN |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Recreational Games/Products/Toys | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.8M | 271.6M |
| IPO Year | 1996 | 2020 |
| Metric | JAKK | SRZN |
|---|---|---|
| Price | $25.25 | $25.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $35.00 | ★ $38.00 |
| AVG Volume (30 Days) | 116.7K | ★ 251.5K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $331,249,000.00 | $3,477,000.00 |
| Revenue This Year | $9.46 | $75.35 |
| Revenue Next Year | $4.36 | N/A |
| P/E Ratio | $195.69 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.87 | $10.11 |
| 52 Week High | $27.22 | $35.00 |
| Indicator | JAKK | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 61.42 |
| Support Level | $21.34 | $24.16 |
| Resistance Level | $27.22 | $27.39 |
| Average True Range (ATR) | 1.12 | 1.98 |
| MACD | -0.11 | 0.63 |
| Stochastic Oscillator | 68.18 | 75.33 |
Jakks Pacific Inc is a multi-product line, multi-brand toy company that designs, produces, markets, sells, and distributes toys and related kid-targeted consumer products, including kids' indoor and outdoor furniture, costumes, and various product lines in the sporting goods and home furnishings space. Its product offerings include Traditional toys and electronics such as Action figures, Toy vehicles, Dolls and accessories, Ride-on toys, Toys for pets, and others. The company's products have been divided into two segments: Toys/Consumer Products and Costumes. It generates the majority of its revenue from the Toys/Consumer Products segment.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).